RxDoctor Payments Data

Michael Dudenhoeffer, DO

Family Medicine · Jefferson City, MONPI 1073517900

Payments from drug & device makers

$4,210in general payments, 2019–2025

Across 260 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kowa Pharmaceuticals America, Inc.$709
  • Novo Nordisk$332
  • AbbVie$309
  • Neurocrine Biosciences, Inc.$262
  • Biohaven Pharmaceuticals, Inc.$201
  • Axsome Therapeutics, Inc.$196
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$4,05996%
  • Education$1514%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,210 in reported general payments places this provider in the 85th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$165,774
Medicare patients
476
Services billed
4,423

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate116$355,275
EliquisApixaban542$257,402
MounjaroTirzepatide117$143,232
XareltoRivaroxaban243$141,041
JardianceEmpagliflozin232$130,532
ShingrixVaricella-Zoster Ge/As01b/Pf601$128,509
OzempicSemaglutide100$108,256
IngrezzaValbenazine Tosylate23$91,816
RexultiBrexpiprazole72$84,266
Trelegy ElliptaFluticasone/Umeclidin/Vilanter88$65,272
LinzessLinaclotide101$64,589
OtezlaApremilast12$55,741
FarxigaDapagliflozin Propanediol74$49,094
RybelsusSemaglutide26$42,773
Risperdal ConstaRisperidone Microspheres15$37,160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Xarelto, Risperdal Consta$89$533,476374 claims
PfizerEliquis$78$257,402542 claims
GSKShingrix, Trelegy Ellipta, Breo Ellipta$48$209,694719 claims
Lilly USA, LLCMounjaro, Trulicity$106$168,207141 claims
Novo NordiskOzempic, Rybelsus$332$151,030126 claims
Neurocrine Biosciences, Inc.Ingrezza$262$91,81623 claims
AbbVieLinzess, Creon, Vraylar$309$87,763143 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$142$86,559150 claims
Otsuka America Pharmaceutical, Inc.Rexulti$65$84,26672 claims
AmgenOtezla$28$55,74112 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$15$33,40130 claims
Astellas Pharma US IncMyrbetriq$94$23,15177 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Jefferson City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →